Simcere Zaiming Enters Exclusive License Agreement with Roche for SIM0660 Global Development

PartnershipSIM0660Positive

AI Analysis

Summary

Simcere Zaiming announced an exclusive global licensing agreement with Roche for the development and commercialization of SIM0660, a tri-specific antibody.

Outcome Details

Exclusive global licensing agreement for development and commercialization

Importance:7/10

Sentiment:

0.70

LicensingPartnershipGlobal RightsAntibody

Related Companies

$2096.HK $RHHBY

Read the original article

Published by PR Newswire Pharma on September 1, 2026 12:28 PM

Read Original